I definitely don’t want to put too much stock into my analysis, as we just simply do not have the data, but I’m unsure what you mean about inhibitors of these gene targets not providing cardioprotection. Maybe you meant the complete cardiosynergy function, which of course there are none.
This is the recent data that I could find about compounds targeting each of these gene pathways for Ca2+ homeostasis.
While they might not provide anti-cancer benefits, they certainly seem to provide a mechanism of cardioprotection. I find Ruxolitinib interesting in this list, as it is a Janus Kinase Inhibitor. The Doan paper found Peficitinib, a Janus and tyrosine kinase inhibitor, was cardiotoxic. Maybe Ruxolitinib would be on this list if it were not for it's efficacy on CaMKII.
Cardioprotection thread, page-387
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $101.6K | 64.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7451 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 408 | 1 |
View Market Depth
| Last trade - 15.53pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.035 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 7255 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |